Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial
Hiddo J.L. Heerspink(University Medical Center Groningen), Janet B. McGill(Washington University in St. Louis), Andreas L. Birkenfeld(Helmholtz Zentrum München), Linong Ji(Peking University), Jay S. Skyler(University of Miami), Per‐Henrik Groop(University of Helsinki), David Z.I. Cherney(University Health Network), Katherine R. Tuttle(Providence Regional Medical Center Everett), Peter Kolkhof(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Charlie Scott(Bayer (United Kingdom)), Chantal Mathieu(KU Leuven), Robert Lawatscheck(Bayer (Germany)), Peter Rossing(Steno Diabetes Centers), Sylvia E. Rosas(Joslin Diabetes Center), Richard E. Pratley(Translational Research Institute for Metabolism and Diabetes), Robert Edfors(Bayer (Germany)), Markus F. Scheerer(Bayer (Germany)), Helen M. Colhoun(Edinburgh Cancer Research)
Cited by 57
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
|The Lancet|2004|3.8k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k